File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis
  • Basic View
  • Metadata View
  • XML View
TitleEvaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis
 
AuthorsWang, Y2
Liu, YH1
Mai, SJ2
He, LJ2
Liao, YJ2
Deng, HX2
Guan, XY2
Zeng, YX2
Kung, HF2
Xie, D2
 
Issue Date2010
 
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
 
CitationJournal Of Gastroenterology And Hepatology, 2010, v. 25 n. 6, p. 1123-1128 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1746.2009.06205.x
 
AbstractBackground and Aim: Hepatocellular carcinoma (HCC) is a common human cancer worldwide. The levels of serum clusterin in HCC patients and its potential diagnostic significance is not clear. We aimed to evaluate the clinical use of serum clusterin levels as a surveillance tool for HCC with hepatitis B virus (HBV) related cirrhosis. Methods: Twenty-two cases of healthy subjects, 31 cases of HBV carriers, 26 patients with chronic hepatitis B, 29 patients with cirrhosis, and 76 patients with HCC were enrolled in this study. Serum levels of clusterin were measured by a sandwich enzyme-linked immunosorbent assay. Results: The serum clusterin levels in HCC patients were significantly lower than that in healthy, HBV carriers and chronic hepatitis B, but statistically higher than in cirrhosis patients. Receiver operator characteristic (ROC) curve indicated that a serum clusterin value of 50 μg/mL yielded the best sensitivity (91%) and specificity (83%) for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related cirrhosis. The optimal alpha fetoprotein (AFP) cutoff value was 15 ng/mL and was inferior to the clusterin value of 50 μg/mL, the area under the ROC curves being 0.937 versus 0.781, respectively (P < 0.05). Conclusions: Serum clusterin was more sensitive and specific than serum AFP for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related liver cirrhosis, and may be a useful surveillance tool of HCC based on HBV-related cirrhosis. © 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
 
ISSN0815-9319
2013 Impact Factor: 3.627
 
DOIhttp://dx.doi.org/10.1111/j.1440-1746.2009.06205.x
 
ISI Accession Number IDWOS:000278110500019
Funding AgencyGrant Number
Foundation of Guangzhou Science and Technology Bureau2005Z1-E0131
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

This study was supported by the Foundation of Guangzhou Science and Technology Bureau (2005Z1-E0131), the Major State Basic Research Program of China (2006CB910104) and the 863 Project of China (2007AA021901)

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWang, Y
 
dc.contributor.authorLiu, YH
 
dc.contributor.authorMai, SJ
 
dc.contributor.authorHe, LJ
 
dc.contributor.authorLiao, YJ
 
dc.contributor.authorDeng, HX
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorKung, HF
 
dc.contributor.authorXie, D
 
dc.date.accessioned2010-10-31T10:39:07Z
 
dc.date.available2010-10-31T10:39:07Z
 
dc.date.issued2010
 
dc.description.abstractBackground and Aim: Hepatocellular carcinoma (HCC) is a common human cancer worldwide. The levels of serum clusterin in HCC patients and its potential diagnostic significance is not clear. We aimed to evaluate the clinical use of serum clusterin levels as a surveillance tool for HCC with hepatitis B virus (HBV) related cirrhosis. Methods: Twenty-two cases of healthy subjects, 31 cases of HBV carriers, 26 patients with chronic hepatitis B, 29 patients with cirrhosis, and 76 patients with HCC were enrolled in this study. Serum levels of clusterin were measured by a sandwich enzyme-linked immunosorbent assay. Results: The serum clusterin levels in HCC patients were significantly lower than that in healthy, HBV carriers and chronic hepatitis B, but statistically higher than in cirrhosis patients. Receiver operator characteristic (ROC) curve indicated that a serum clusterin value of 50 μg/mL yielded the best sensitivity (91%) and specificity (83%) for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related cirrhosis. The optimal alpha fetoprotein (AFP) cutoff value was 15 ng/mL and was inferior to the clusterin value of 50 μg/mL, the area under the ROC curves being 0.937 versus 0.781, respectively (P < 0.05). Conclusions: Serum clusterin was more sensitive and specific than serum AFP for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related liver cirrhosis, and may be a useful surveillance tool of HCC based on HBV-related cirrhosis. © 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2010, v. 25 n. 6, p. 1123-1128 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1746.2009.06205.x
 
dc.identifier.citeulike7277171
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1440-1746.2009.06205.x
 
dc.identifier.epage1128
 
dc.identifier.hkuros175309
 
dc.identifier.isiWOS:000278110500019
Funding AgencyGrant Number
Foundation of Guangzhou Science and Technology Bureau2005Z1-E0131
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

This study was supported by the Foundation of Guangzhou Science and Technology Bureau (2005Z1-E0131), the Major State Basic Research Program of China (2006CB910104) and the 863 Project of China (2007AA021901)

 
dc.identifier.issn0815-9319
2013 Impact Factor: 3.627
 
dc.identifier.issue6
 
dc.identifier.pmid20594228
 
dc.identifier.scopuseid_2-s2.0-77952963730
 
dc.identifier.spage1123
 
dc.identifier.urihttp://hdl.handle.net/10722/124521
 
dc.identifier.volume25
 
dc.languageeng
 
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
 
dc.publisher.placeAustralia
 
dc.relation.ispartofJournal of Gastroenterology and Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshCarcinoma, Hepatocellular - blood - complications - epidemiology
 
dc.subject.meshChina - epidemiology
 
dc.subject.meshClusterin - blood
 
dc.subject.meshDisease Progression
 
dc.subject.meshEnzyme-Linked Immunosorbent Assay
 
dc.subject.meshFemale
 
dc.subject.meshFollow-Up Studies
 
dc.subject.meshHepatitis B, Chronic - blood - complications - epidemiology
 
dc.subject.meshHumans
 
dc.subject.meshLiver Cirrhosis - blood - epidemiology - virology
 
dc.subject.meshLiver Neoplasms - blood - complications - epidemiology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPrevalence
 
dc.subject.meshPrognosis
 
dc.subject.meshRetrospective Studies
 
dc.subject.meshSensitivity and Specificity
 
dc.subject.meshalpha-Fetoproteins - metabolism
 
dc.titleEvaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wang, Y</contributor.author>
<contributor.author>Liu, YH</contributor.author>
<contributor.author>Mai, SJ</contributor.author>
<contributor.author>He, LJ</contributor.author>
<contributor.author>Liao, YJ</contributor.author>
<contributor.author>Deng, HX</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2010-10-31T10:39:07Z</date.accessioned>
<date.available>2010-10-31T10:39:07Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Journal Of Gastroenterology And Hepatology, 2010, v. 25 n. 6, p. 1123-1128</identifier.citation>
<identifier.issn>0815-9319</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/124521</identifier.uri>
<description.abstract>Background and Aim: Hepatocellular carcinoma (HCC) is a common human cancer worldwide. The levels of serum clusterin in HCC patients and its potential diagnostic significance is not clear. We aimed to evaluate the clinical use of serum clusterin levels as a surveillance tool for HCC with hepatitis B virus (HBV) related cirrhosis. Methods: Twenty-two cases of healthy subjects, 31 cases of HBV carriers, 26 patients with chronic hepatitis B, 29 patients with cirrhosis, and 76 patients with HCC were enrolled in this study. Serum levels of clusterin were measured by a sandwich enzyme-linked immunosorbent assay. Results: The serum clusterin levels in HCC patients were significantly lower than that in healthy, HBV carriers and chronic hepatitis B, but statistically higher than in cirrhosis patients. Receiver operator characteristic (ROC) curve indicated that a serum clusterin value of 50 &#956;g/mL yielded the best sensitivity (91%) and specificity (83%) for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related cirrhosis. The optimal alpha fetoprotein (AFP) cutoff value was 15 ng/mL and was inferior to the clusterin value of 50 &#956;g/mL, the area under the ROC curves being 0.937 versus 0.781, respectively (P &lt; 0.05). Conclusions: Serum clusterin was more sensitive and specific than serum AFP for differentiating HCC patients with HBV-related cirrhosis from those with HBV-related liver cirrhosis, and may be a useful surveillance tool of HCC based on HBV-related cirrhosis. &#169; 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.</description.abstract>
<language>eng</language>
<publisher>Wiley-Blackwell Publishing Asia. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/JGH</publisher>
<relation.ispartof>Journal of Gastroenterology and Hepatology</relation.ispartof>
<subject.mesh>Carcinoma, Hepatocellular - blood - complications - epidemiology</subject.mesh>
<subject.mesh>China - epidemiology</subject.mesh>
<subject.mesh>Clusterin - blood</subject.mesh>
<subject.mesh>Disease Progression</subject.mesh>
<subject.mesh>Enzyme-Linked Immunosorbent Assay</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Follow-Up Studies</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - blood - complications - epidemiology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Liver Cirrhosis - blood - epidemiology - virology</subject.mesh>
<subject.mesh>Liver Neoplasms - blood - complications - epidemiology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Prevalence</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Retrospective Studies</subject.mesh>
<subject.mesh>Sensitivity and Specificity</subject.mesh>
<subject.mesh>alpha-Fetoproteins - metabolism</subject.mesh>
<title>Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1111/j.1440-1746.2009.06205.x</identifier.doi>
<identifier.pmid>20594228</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77952963730</identifier.scopus>
<identifier.hkuros>175309</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77952963730&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>25</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>1123</identifier.spage>
<identifier.epage>1128</identifier.epage>
<identifier.isi>WOS:000278110500019</identifier.isi>
<publisher.place>Australia</publisher.place>
<identifier.citeulike>7277171</identifier.citeulike>
</item>
Author Affiliations
  1. Guangdong Provincial People's Hospital
  2. Sun Yat-Sen University